<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Alexza Pharmaceuticals Inc</title>
	<atom:link href="http://www.stockbloghub.com/tag/alexza-pharmaceuticals-inc/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Sun, 20 May 2012 20:27:31 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(ALXA) Company News for October 5, 2011 &#8211; Corporate Summary</title>
		<link>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644</link>
		<comments>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644#comments</comments>
		<pubDate>Thu, 06 Oct 2011 15:16:49 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexandria Real Estate Equities Inc]]></category>
		<category><![CDATA[Alexion Pharmaceuticals Inc]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[ALXN]]></category>
		<category><![CDATA[ARE]]></category>
		<category><![CDATA[General Maritime Corporation]]></category>
		<category><![CDATA[GMR]]></category>
		<category><![CDATA[NRG]]></category>
		<category><![CDATA[NRG Energy Inc.]]></category>
		<category><![CDATA[Red Hat Inc.]]></category>
		<category><![CDATA[RHT]]></category>
		<category><![CDATA[S]]></category>
		<category><![CDATA[Sprint Nextel Corporation]]></category>
		<category><![CDATA[Transcept Pharmaceuticals Inc]]></category>
		<category><![CDATA[TSPT]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=84644</guid>
		<description><![CDATA[•    Drug developer Transcept Pharmaceuticals Inc.’s (NASDAQ:TSPT) shares increased 33.77% to close at $8.08 after the company&#8217;s experimental sleep treatment got approved from the regulators •    Share prices of General Maritime Corp. (NYSE:GMR) declined 7.35%  after the company reported its plans for a possible restructuring •    Shares of power company NRG Energy Inc. (NYSE:NRG) shed 1.81% to close at $19.57 after the company lowered down its earnings outlook for 2011 •    Software company Red Hat Inc. (NYSE:RHT) announced that it would acquire software developer Gluster Inc. in a deal worth $136 million •    Share prices of phone carrier Sprint-Nextel (NYSE:S) advanced 4.76% on news that the company will offer the iPhone 4S on its inaugural day on 14th October •    Analysts at Goldman Sachs upgraded shares of Kinder Morgan (NYSE:KMI) ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/10/06/alxa-company-news-for-october-5-2011-corporate-summary/84644/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXA) Alexza Pharmaceuticals &#8211; Bull of the Day</title>
		<link>http://www.stockbloghub.com/2011/03/17/alxa-alexza-pharmaceuticals-bull-of-the-day/68961</link>
		<comments>http://www.stockbloghub.com/2011/03/17/alxa-alexza-pharmaceuticals-bull-of-the-day/68961#comments</comments>
		<pubDate>Thu, 17 Mar 2011 16:59:40 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=68961</guid>
		<description><![CDATA[We are upgrading our rating on shares of Alexza Pharmaceuticals (ALXA) to Outperform and raising our price target to $3 per share. We believe the company is on track to re-file the new drug application (NDA) on AZ-004 (Staccato loxapine) for the treatment of acute agitation in patients with schizophrenia or bipolar disorder by the end of July 2011. Based on our analysis of the complete response letter (CRL) received on October 8, 2010, and our numerous conversations with management, we believe Alexza is adequately prepared to file a full response with an excellent chance to receive approval in January 2012. We see multiple catalysts in 2011, including the NDA filing, an FDA panel review, and a potential deal for AZ-004 commercialization, prior to the FDA&#8217;s decision in early 2012 ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2011/03/17/alxa-alexza-pharmaceuticals-bull-of-the-day/68961/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYPB) Cypress Bioscience Reports Wider Loss</title>
		<link>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647</link>
		<comments>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647#comments</comments>
		<pubDate>Fri, 26 Nov 2010 04:18:57 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[Forest Laboratories Inc.]]></category>
		<category><![CDATA[FRX]]></category>
		<category><![CDATA[MDRNA Inc]]></category>
		<category><![CDATA[MRNA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=59647</guid>
		<description><![CDATA[Cypress Bioscience, Inc. (CYPB) reported a net loss of 94 cents per share in the third quarter, significantly higher than the Zacks Consensus Estimate of a loss of 33 cents and the year ago loss of 12 cents. Despite an increase in revenues, higher operating expenses led to the wider loss in the reported quarter. Quarter in Detail Third-quarter revenues came in at $8 million, well above the Zacks Consensus Estimate of $5 million and 45.3% above the year-ago revenues of $5.5 million. Third quarter revenues consisted of $7.2 million in commercial revenues and $0.8 million in revenues under collaborative agreements. Commercial revenues of $7.2 million included royalty revenues of $3.2 million and $3.6 million in co-promotion reimbursement in connection with Savella. The co-promotion amount includes a one-time fee of ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/11/25/cypb-cypress-bioscience-reports-wider-loss/59647/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(CYPB) Cypress Bioscience Signs Deal With Marina Biotech</title>
		<link>http://www.stockbloghub.com/2010/09/16/cypb-cypress-bioscience-signs-deal-with-marina-biotech/49832</link>
		<comments>http://www.stockbloghub.com/2010/09/16/cypb-cypress-bioscience-signs-deal-with-marina-biotech/49832#comments</comments>
		<pubDate>Thu, 16 Sep 2010 16:22:17 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Biotechnology]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[CNS]]></category>
		<category><![CDATA[Cohen & Steers Inc.]]></category>
		<category><![CDATA[CYPB]]></category>
		<category><![CDATA[Cypress Bioscience Inc]]></category>
		<category><![CDATA[MDRNA Inc]]></category>
		<category><![CDATA[MRNA]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=49832</guid>
		<description><![CDATA[Recently, Cypress Bioscience, Inc. (CYPB) announced that it has inked a deal with Marina Biotech, Inc. (MRNA). The deal, which allows Cypress to acquire Marina’s patent rights and technology for autism candidate, carbetocin, is expected to boost the central nervous system pipeline (CNS) at Cypress. The asset purchase agreement will see Cypress making an upfront payment of $750,000 to Marina. However, the value of the deal can increase to $27 million subject to the attainment of certain late-stage clinical and regulatory milestones Incorporatedluding the approval of the candidate by the US Food and Drug Administration (FDA). Moreover, Cypress will be responsible for financing all continuing development activities and will pay single-digit royalties to Marina on sales of the drug, if it hits the market. Carbetocin, an intranasal therapy, is a ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2010/09/16/cypb-cypress-bioscience-signs-deal-with-marina-biotech/49832/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>(ALXA) Alexza Pharmaceuticals Files New Drug Application</title>
		<link>http://www.stockbloghub.com/2009/12/17/alxa-alexza-pharmaceuticals-files-new-drug-application/23155</link>
		<comments>http://www.stockbloghub.com/2009/12/17/alxa-alexza-pharmaceuticals-files-new-drug-application/23155#comments</comments>
		<pubDate>Fri, 18 Dec 2009 01:08:54 +0000</pubDate>
		<dc:creator>vitalstocks</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Alexza Pharmaceuticals Inc]]></category>
		<category><![CDATA[ALXA]]></category>
		<category><![CDATA[IM]]></category>
		<category><![CDATA[Ingram Micro Inc.]]></category>
		<category><![CDATA[PAI]]></category>
		<category><![CDATA[Western Asset Income Fund]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=23155</guid>
		<description><![CDATA[On December 14, 2009, roughly a month ahead of our forecast, Alexza Pharmaceuticals (ALXA) announced it had filed the new drug application (NDA) on AZ-004. The news follows the completion of the five non-pivotal safety and supporting studies earlier in the year, and the pre-NDA meeting held with the U.S. FDA in June 2009. In total, AZ-004 has been tested in over 1,600 patients in 13 clinical programs Incorporatedluding the two pivotal phase III trials that both met their primary endpoint. We expect the U.S. FDA will respond accepting the application around early February 2010. Assuming a standard 10-month PDUFA review, Alexza should have a response letter from the FDA by the middle of October 2010. Next up for Alexza will be securing a commercialization partnership for AZ-004. Management has ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/12/17/alxa-alexza-pharmaceuticals-files-new-drug-application/23155/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

